C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
McNamara
D J
DJ
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA. mcnamad@aa.wl.com
Dobrusin
E
E
Leonard
D M
DM
Shuler
K R
KR
Kaltenbronn
J S
JS
Quin
J
J
Bur
S
S
Thomas
C E
CE
Doherty
A M
AM
Scholten
J D
JD
Zimmerman
K K
KK
Gibbs
B S
BS
Gowan
R C
RC
Latash
M P
MP
Leopold
W R
WR
Przybranowski
S A
SA
Sebolt-Leopold
J S
JS
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002460:Cell Line; D004151:Dipeptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D015394:Molecular Structure; D009374:Neoplasms, Experimental / Q000188:drug therapy; D017368:Protein Prenylation; D051381:Rats; D014407:Tumor Cells, Cultured; D018631:ras Proteins / Q000378:metabolism*
D000970:Antineoplastic Agents; D004151:Dipeptides; D004791:Enzyme Inhibitors; C108921:PD 152440; C108922:benzyloxycarbonyl-histidyl-N-(2-(benzyloxyphenylmethyl))glycine N-(2-methyl-2-phenylpropyl)amide; D019883:Alkyl and Aryl Transferases; C064911:p21(ras) farnesyl-protein transferase; D018631:ras Proteins